Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

Next Previous
Trial Profile

A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 09 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Cobimetinib (Primary) ; Entrectinib (Primary) ; Vemurafenib (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Gemcitabine; Pemetrexed
  • Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms B-FAST
  • Sponsors Roche

Most Recent Events

  • 03 Sep 2026 Planned End Date changed from 31 Oct 2026 to 30 Jun 2027.
  • 03 Sep 2026 Planned primary completion date changed from 31 Oct 2026 to 30 Jun 2027.
  • 30 Apr 2025 Results assessing efficacy of targeted therapies in patients with unresectable, advanced or metastatic NSCLC selected based on the presence of oncogenic somatic mutations or a positive bTMB score, presented at the 116th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top